Can HRT Cause Bleeding and When Should You Worry?

Hormone replacement therapy can and frequently does cause vaginal bleeding, and in most cases it is a normal, expected side effect rather than a sign of something dangerous. Unscheduled bleeding affects up to about 40% of HRT users, a number that has driven a parallel rise in urgent medical referrals as HRT prescribing has grown. Whether that bleeding warrants concern depends on timing, pattern, and the type of regimen you are on, and the distinction between “annoying but harmless” and “get this checked” is clearer than many people realize.

Why HRT Causes Bleeding in the First Place

Your uterine lining responds directly to the hormones it receives. Estrogen stimulates the endometrium to thicken, while progesterone (or a synthetic progestogen) counterbalances that growth and eventually triggers shedding. When you introduce exogenous hormones through HRT, you are resetting the signals the endometrium receives, and it takes time for the tissue to stabilize under a new hormonal environment. During that adjustment, the lining may shed unevenly or at unexpected times.

The vascular architecture of the endometrium plays a role too. Research has shown that both hyperestrogenic endometria and progestogen-dominant endometria undergo characteristic vascular changes that predispose to irregular bleeding.¹ Combined continuous HRT regimens tend to be predominantly progestogenic, and some of the same fragile blood-vessel changes seen in women on long-term low-dose progestogen-only contraceptives appear to occur in HRT users as well.² In plain terms, the blood vessels feeding the lining become more fragile and prone to small breaks, which translates into spotting or light bleeding that has nothing to do with a disease process.

How Bleeding Patterns Differ by Regimen Type

The two main categories of HRT are sequential (also called cyclic) and continuous combined, and they produce very different bleeding expectations.

With a sequential regimen, you take estrogen daily and add a progestogen for roughly 10 to 14 days each month. This mimics a natural menstrual cycle, and a withdrawal bleed at the end of the progestogen phase is expected. It is designed into the treatment. The bleed should be predictable in timing and moderate in flow. Any bleeding that falls outside that scheduled window counts as “unscheduled” or “unexpected” and deserves attention if it persists.

With a continuous combined regimen, you take estrogen and progestogen together every day with no break. The goal is to avoid regular withdrawal bleeds altogether and eventually reach amenorrhea. But early on, irregular bleeding and spotting are common. A Cochrane review found that irregular bleeding was more than twice as likely under a continuous combined regimen than under a sequential one in the short term.³ The trade-off is that over longer use, the continuous approach was more protective against endometrial hyperplasia and eventually produced less unexpected bleeding than the cyclic approach.

A study comparing first-time users of both regimen types found that roughly 38% of cyclic HRT starters and about 42% of continuous combined starters had at least one visit for unexpected bleeding in the first period of use. After two years, though, the continuous combined group had lower rates of unexpected bleeding than the cyclic group.⁴ So if you are on continuous combined HRT and experiencing spotting in the first several months, you are in a large and well-documented company, and the picture tends to improve with time.

The First Few Months Are the Roughest

This is the single most reassuring fact about HRT-related bleeding: it is heavily front-loaded. In a study tracking daily bleeding records of women on continuous HRT, 80% of all bleeding episodes occurred during the first four months of therapy.⁵ After that window, the endometrium typically settles into a stable, thin state and bleeding tapers off or stops entirely.

By around nine months of continuous combined therapy, one study found that roughly 89% of fully postmenopausal women had achieved amenorrhea, with late perimenopausal women not far behind at about 84%.⁶ The practical takeaway is that if you start continuous combined HRT and have spotting in months one through three or four, that is the normal trajectory. Bleeding that starts for the first time after you have already been settled on a stable regimen for six months or more is a different story and warrants investigation.

Does the Delivery Method Matter

It does. Whether you take HRT as a pill, a patch, or a gel can influence how much unscheduled bleeding you experience. A systematic review of uterine bleeding across different formulations found that oral HRT generally had a better bleeding profile than transdermal formulations. Over the course of a year, cumulative amenorrhea rates ranged from roughly 18% to 61% with oral therapies, compared with about 9% to 27% with transdermal HRT.⁷ The wide ranges reflect the fact that specific hormone combinations matter a great deal. For instance, oral estradiol with progesterone achieved amenorrhea in roughly 56% of women, while an estradiol/levonorgestrel patch managed only about 16%.

That said, another systematic review comparing transdermal and oral HRT directly found that amenorrhea rates eventually equalized with longer use.⁸ The route of administration is not the only factor in play, and many women choose transdermal HRT for reasons unrelated to bleeding, such as avoiding the first-pass liver effect. If you are on a patch and experiencing more spotting than expected, the route itself may be contributing, and discussing a formulation change with your prescriber is reasonable.

When Bleeding Is Not Just Hormonal

Not all bleeding during HRT comes from the endometrium reacting to hormones. Structural problems inside the uterus can be responsible, and HRT can unmask them. A large hysteroscopy study found intrauterine pathology in nearly 47% of women who had abnormal bleeding while on HRT.⁹ Polyps were among the most common findings. Functional (hormone-responsive) endometrium was more common in HRT users than in women with postmenopausal bleeding who were not on HRT, but the frequency of structural abnormalities was still striking.

Submucous fibroids are another culprit. Women with fibroids projecting into the uterine cavity had more than four times the odds of prolonged and heavy progestogen-associated bleeding compared to women without them, and they also experienced more frequent intermenstrual bleeding.¹⁰ If your bleeding is persistently heavy or does not follow the expected pattern of improvement over time, fibroids or polyps are worth investigating even if you assume the hormones are entirely to blame.

When You Should Actually Worry

The general guidance is straightforward, even if individual clinical decisions are nuanced. Bleeding that falls within these categories should prompt you to contact your prescriber:

New bleeding after amenorrhea: If you have been on continuous combined HRT for six or more months without bleeding and it starts up again, that change needs investigation.
Heavy or prolonged bleeding on any regimen: Soaking through a pad every hour or two, or bleeding that lasts significantly longer than a typical period, is not typical HRT adjustment bleeding.
Bleeding that persists beyond six months: The first four to six months of irregular spotting are widely tolerated as normal on continuous regimens. Bleeding that continues unchanged beyond that window raises questions.
Unscheduled bleeding on sequential HRT: On a cyclic regimen, bleeding outside the expected withdrawal window warrants a closer look.
Any postmenopausal bleeding if you are not on HRT: This is always a reason to be evaluated, even if it is a single episode.

The worry behind these guidelines is endometrial hyperplasia or, less commonly, endometrial cancer. The Cochrane review noted that while continuous combined therapy was more protective against hyperplasia over time than sequential therapy, the risk is not zero under either approach.³ Bleeding in itself is a poor predictor of malignancy, but it is the main symptom that leads to early detection, which is why clinicians take it seriously even when the odds favor a benign explanation.

How Doctors Investigate HRT-Related Bleeding

The first-line investigation is usually a transvaginal ultrasound to measure endometrial thickness. A thin endometrial stripe is reassuring. One study found that when the endometrium measured less than 5 mm, biopsies consistently showed either inactive, atrophic tissue or were insufficient to even yield a sample, and no hyperplastic or malignant changes were found.¹¹ A thicker endometrium does not automatically mean something is wrong, but it does move you along the diagnostic pathway.

For women on HRT, a commonly used threshold for further investigation is an endometrial thickness above 10 mm, though this is higher than the 4-5 mm cutoff used for postmenopausal women who are not taking hormones.¹² This difference exists because HRT itself thickens the endometrium, so the baseline is higher. One study examining the diagnostic accuracy of ultrasound in HRT users identified an optimal endometrial thickness cutoff around 7.5 mm, which yielded high sensitivity and specificity for detecting significant pathology.¹³ The exact threshold your doctor uses may vary based on clinical context and local guidelines.

If the ultrasound is inconclusive or the endometrium is thick, the next steps include endometrial biopsy (a quick office procedure that samples the lining) and sometimes hysteroscopy, which allows direct visualization of the uterine cavity. Clinical practice recommendations suggest that women on HRT whose bleeding is recurrent or whose endometrial thickness exceeds the relevant threshold should have tissue sampling to rule out hyperplasia or malignancy.¹⁴ The investigation process is usually quick and, while not exactly comfortable, is well tolerated.

Adjusting Your Regimen to Reduce Bleeding

If your bleeding is bothersome but investigation shows nothing concerning, there are several practical options. Abnormal bleeding on progesterone-only, combined sequential, or combined continuous regimens can often be improved by changing the type of progestogen, adjusting the progestogen dose, tweaking the estrogen-to-progestogen ratio, or switching to a different formulation entirely.¹⁵ For instance, a woman on a continuous combined oral regimen who has persistent spotting might do better with a different progestogen or a slightly higher progestogen dose.

Withdrawal bleeding has historically been one of the biggest barriers to staying on HRT. A study found that while many troublesome side effects of HRT could be managed by adjusting dose or hormone source, postmenopausal women rated withdrawal bleeding as the single most negative factor in their decision to continue therapy.¹⁶ This is why the development of continuous combined regimens, which eliminate scheduled bleeds, was such a significant advance. If you are on a sequential regimen and the monthly bleed is what is bothering you, switching to a continuous combined regimen is often an option, particularly if you are clearly postmenopausal.

The Levonorgestrel Intrauterine System as an Alternative

One option that has gained popularity is delivering the progestogen component of HRT directly to the uterus via a levonorgestrel-releasing intrauterine system (the hormonal IUD sometimes known by the brand name Mirena). This device releases a small amount of progestogen locally into the uterine lining while you take estrogen separately, by pill, patch, or gel. A clinical review found that the LNG-IUS offers highly effective endometrial protection and can effectively manage bleeding problems through the transition from perimenopause into menopause, with many women eventually achieving amenorrhea.¹⁷

The appeal is that the progestogen goes where it is needed (the endometrium) and very little circulates systemically, which can reduce progestogen-related side effects like bloating and mood changes while still protecting the lining. For women who have had persistent bleeding problems with oral or transdermal progestogens, the LNG-IUS can be a practical solution.

Compounded Hormones and Higher Bleeding Rates

A point that receives less attention than it deserves: not all hormone preparations perform the same when it comes to bleeding. Compounded bioidentical hormones, which are mixed by specialty pharmacies rather than manufactured under FDA oversight, have been linked to substantially higher rates of abnormal uterine bleeding compared with FDA-approved therapies. In one safety assessment, roughly 55% of women with an intact uterus who used compounded hormones experienced at least one episode of abnormal bleeding, compared with about 15% of women on FDA-approved HRT.¹⁸ The odds of bleeding were roughly eight times higher with compounded products.

The reasons likely involve inconsistent dosing and the absence of standardized progestogen delivery. Compounded preparations lack the rigorous bioequivalence testing that FDA-approved products undergo, and the estrogen-to-progestogen balance may not be optimized for endometrial stability. If you are on compounded hormones and experiencing persistent or frequent bleeding, this discrepancy is worth discussing with your prescriber. The bleeding itself may be a signal that the endometrium is not receiving adequate progestogenic opposition, which is the very thing that protects against hyperplasia.

Bleeding and the Decision to Stop HRT

Bleeding is one of the top reasons women discontinue hormone therapy. In a study examining why women stopped HRT, about 19% cited weariness of bleeding as their primary reason, while 35% cited negative side effects more broadly, and 25% mentioned fear of cancer and blood clots.¹⁹ The irony is that bleeding and fear of cancer are closely linked in women’s minds: unexpected bleeding triggers anxiety about endometrial cancer, which in turn drives both urgent referrals and treatment abandonment.

This anxiety is understandable but often disproportionate to the actual risk. Most unscheduled bleeding on HRT is benign, caused by the endometrium adjusting to the hormonal environment, local vascular fragility, or structural findings like polyps that are overwhelmingly noncancerous. The goal of investigation is not to confirm a dangerous diagnosis but to rule one out, and in most cases it does. Women who stop HRT because of bleeding may lose the benefits they started therapy for, including relief from hot flashes, bone protection, and improved quality of life, when a regimen adjustment or a brief investigation could have resolved the issue. If bleeding is making you consider stopping, a conversation about alternatives with your prescriber is a better first step than discontinuation.

Perimenopause Versus Full Menopause

Your menopausal status when you start HRT matters for what bleeding pattern to expect. Women who begin HRT during perimenopause, when their ovaries are still intermittently producing estrogen on their own, tend to have more unpredictable bleeding than women who start well after their final period. This is because the exogenous hormones are layered on top of erratic endogenous production, making the total hormonal signal to the endometrium inconsistent from day to day.

Sequential regimens are generally preferred during perimenopause for this reason: they work with the body’s remaining cycling tendency and produce a predictable withdrawal bleed. Continuous combined regimens, which aim for no bleeding at all, tend to work best in fully postmenopausal women whose ovaries are no longer contributing meaningful estrogen. Starting a continuous combined regimen too early, before periods have fully ceased, is one of the most common causes of frustrating irregular bleeding that does not settle. The study noted earlier found that by nine months of continuous combined therapy, 89% of postmenopausal women but only about 84% of late perimenopausal women had achieved amenorrhea, a modest but real gap.⁶ If you are perimenopausal and experiencing persistent breakthrough bleeding on continuous combined HRT, switching to a sequential regimen until you are further along the menopausal transition is a standard and effective strategy.